Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 283

Short Communication

A randomized pilot study of triple Nucleotide reverse transcriptase inhibitors therapy with tenofovir, zidovudine (AZT) plus emtricitabine in antiretroviral naive HIV-1 infected patients – The TEAZE study

Markus Bickel
  • Markus Bickel
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Christoph Stephan
  • Christoph Stephan
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Tessa Lennemann
  • Tessa Lennemann
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Pavel Khaykin
  • Pavel Khaykin
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Gabi Nisius
  • Gabi Nisius
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Hans Reinhard Brodt
  • Hans Reinhard Brodt
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Schlomo Staszewski
  • Schlomo Staszewski
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar
Annette Haberl
  • Annette Haberl
  • HIV Centre, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
  • Google Scholar


  •  Accepted: 19 April 2010
  •  Published: 31 August 2010

Abstract

A randomized pilot-study to evaluate the virologic efficacy of Tenofovir-DF (TDF) 300 mg/Emtricitabine (FTC) 200 mg once daily plus Zidovudine (AZT) 250 mg twice daily (armA) or 300 mg BID (armB) in naïve HIV-1 infected patients. Twenty patients with a median CD4 cell count of 288 cells/µl (standard deviation (SD): ± 109) and a median viral load of 66.400 HIV RNA copies/ml (SD: ± 70.700) were included. Three patients in armA and one in armB had a single HIV-RNA-PCR measurement of > 50 copies/ml (p = 0.58). The combined median CD4 cells increased by 188 cells/µl at week 48. TDF 300 mg/FTC 200 mg once daily in combination with AZT 250 mg or 300 mg twice daily was well tolerated and no virologic failure occurred.

 

Key words: Class sparing, nucleoside reverse transcriptase inhibitor (NRTI), K65R, drug interaction